A5043788538- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Lung Cancer Research Studies
- Liver physiology and pathology
- Cutaneous lymphoproliferative disorders research
- Immune cells in cancer
- Genetic factors in colorectal cancer
- Genomics and Chromatin Dynamics
- Plant Virus Research Studies
- Plant and Fungal Interactions Research
- Genetics and Neurodevelopmental Disorders
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Pancreatic function and diabetes
- Cancer-related gene regulation
- Plant-Microbe Interactions and Immunity
- Inflammatory Bowel Disease
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
Roche (United States)
2024
Translational Therapeutics (United States)
2019
University of Pennsylvania
2019
California Institute for Regenerative Medicine
2019
University of California, Berkeley
2012
Gene silencing by chromatin compaction is integral to establishing and maintaining cell fates. Trimethylated histone 3 lysine 9 (H3K9me3)-marked heterochromatin reduced in embryonic stem cells compared differentiated cells. However, the establishment dynamics of closed regions at protein-coding genes, embryologic development, remain elusive. We developed an antibody-independent method isolate map compacted from low-cell number samples. discovered high levels heterochromatin,...
In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 patients with untreated, resectable, stage IB-IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 analysis, MPR 20% (95% confidence interval, 14-28%). With a minimum duration follow-up 3 years, 3-year survival rate 80%...
Abstract High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had advanced solid TMB ≥10 mut/Mb by any Clinical Laboratory Improvement Amendments (CLIA)–certified assay. The preplanned primary endpoint was objective response rate (ORR) in ≥16 FoundationOne testing [F1(CDx)]. Patients F1(CDx) and...
Barley stripe mosaic virus North Dakota 18 (ND18), Beijing (BJ), Xinjiang (XJ), Type (TY) and CV21 strains are unable to infect the Brachypodium distachyon Bd3-1 inbred line, which harbours a resistance gene designated Bsr1 , but Norwich (NW) strain is virulent on Bd3-1. Analysis of ND18 NW genomic RNA reassortants RNAβ mutants demonstrates that two amino acids within helicase motif triple block 1 (TGB1) movement protein have major effects their phenotypes. Resistance correlates with an...
Introduction Neoadjuvant chemoimmunotherapy has achieved overall survival (OS) benefit for patients with resectable non-small cell lung cancer (NSCLC). Here, we present outcomes after 3 years of follow-up from the first reported study neoadjuvant atezolizumab+chemotherapy. Methods This open-label, multicenter single-arm investigator-initiated phase II conducted at three US hospitals tested up to four cycles atezolizumab, carboplatin, and nab-paclitaxel prior surgery. Major pathological...
Abstract Introduction: Neoadjuvant chemoimmunotherapy is promising in improving outcomes for patients with resectable lung cancer the phase III setting, though data are immature at this time overall survival (OS). Here, we present after 3 years of follow-up from first reported study neoadjuvant immunotherapy + chemotherapy population. Methods: This open-label, multi-center single-arm investigator-initiated II was conducted three hospitals USA. atezolizumab, carboplatin, and nab-paclitaxel...
Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
<div>Abstract<p>High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had advanced solid TMB ≥10 mut/Mb by any Clinical Laboratory Improvement Amendments (CLIA)–certified assay. The preplanned primary endpoint was objective response rate (ORR) in ≥16 FoundationOne testing [F1(CDx)]. Patients...
<div>Abstract<p>High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had advanced solid TMB ≥10 mut/Mb by any Clinical Laboratory Improvement Amendments (CLIA)–certified assay. The preplanned primary endpoint was objective response rate (ORR) in ≥16 FoundationOne testing [F1(CDx)]. Patients...
Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study